Treatment for diabetes using a gastrin/CCK receptor ligand and a

Details Treatment for diabetes using a gastrin/CCK receptor ligand and a Treatment for diabetes using a gastrin/CCK receptor ligand and a

1992-12-14

1999-03-23

Spector, Lorraine

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514866, 530309, 530399, A61K 3816, C07K 14495

Patent

active

058859560

ABSTRACT:
A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGF receptor ligand, e.g. TGF.alpha., in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGF.alpha. gene.

REFERENCES:
L.G. Durrant et al. Brit. J. Cancer 63:67-70 1991.
G.S. Baldwin & Q-X Zhang Cancer Res. 52:2261-74/15/92.
M. Korc J. Clin Invest. 92:1113-4 Sep. 1993.
T.C. Wang et al. J. Clin. Invest. 92:1349-56 Sep. 1993.

Affiliated with

Also associated with

Rating

Treatment for diabetes using a gastrin/CCK receptor ligand and a does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment for diabetes using a gastrin/CCK receptor ligand and a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for diabetes using a gastrin/CCK receptor ligand and a will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2125445